Netramark is a company developing machine learning-based software-as-a-service (SaaS). It was founded in 2015 by Joseph Geraci and Richard Brooks. The company also entered into a joint venture with Juvenescence AI in 2018 under the name of NetraPharma, which focuses on establishing a computational drug discovery platform. Netramark is headquartered in Toronto, Ontario, Canada.
Netramark's services are composed of its three proprietary technologies: NetraPlay, NetraAI, and DeepCrush. NetraPlay functions as an interface that allows users to determine and manipulate data inputs and outputs through the use of augmented intelligence. NetraAI is a machine learning tool intended to analyze small datasets, although when DeepCrush's functionality is activated, it is able to analyze datasets of all sizes and classify them based on identified correlates. In Netramark's NetraPharma venture, all of these technologies are employed alongside NetraHealthAtlas, a repository of pharmacological-related data.
Classical and Quantum Machine Learning Applied To Predicting Placebo
Response For Clinical Trials In Bipolar Disorder: Recent Results
Joseph Geraci, Bernard Wong, Jalal Ziauddin, Siddhant Jain, Paul Leonczyk, Kim I. Bishop
Interview with Joseph Geraci
NetraMark: Next-Gen AI for Disease Definition, Patient Stratification,
and Placebo Effect